Sonata Therapeutics Overview
- Year Founded
-
2022
- Status
-
Out of Business
- Employees
-
54
- Latest Deal Type
-
Out of Business
Sonata Therapeutics General Information
Description
Developer of small-molecule drugs and genetic therapeutics designed for oncologic indications, as well as exploratory efforts in fibrosis and autoimmune disorders. The company's platform creates drugs based on a systematic, comprehensive characterization of the microenvironment in diseases with high unmet medical needs, with preclinical programs, enabling patients to get curative treatments for serious diseases.
Contact Information
Website
www.sonatatx.comCorporate Office
- 500 Arsenal Street
- Suite 100
- Watertown, MA 02472
- United States
Corporate Office
- 500 Arsenal Street
- Suite 100
- Watertown, MA 02472
- United States
Sonata Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Out of Business | Completed | Out of Business | ||||
| 2. Early Stage VC | 01-Jan-2023 | Completed | Generating Revenue | |||
| 1. Merger of Equals | 18-May-2022 | Completed | Generating Revenue |
Sonata Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Sonata Therapeutics Patents
Sonata Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024151666-A1 | Carboxylic acid analogs as gpx4 inhibitors and use thereof | Inactive | 09-Jan-2023 | ||
| WO-2024129780-A1 | Benzimidazole derivatives as gpx4 inhibitors | Inactive | 13-Dec-2022 | ||
| WO-2024030651-A1 | Gpx4 inhibitors and use thereof | Inactive | 05-Aug-2022 | ||
| WO-2023129564-A1 | Degraders of grk2 and uses thereof | Inactive | 27-Dec-2021 | ||
| WO-2023129564-A9 | Degraders of grk2 and uses thereof | Inactive | 27-Dec-2021 | C07D401/14 |
Sonata Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Sonata Therapeutics Acquisitions (2)
Sonata Therapeutics’s most recent deal was a Merger/Acquisition with Cygnal.. The deal was made on 18-May-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Cygnal. | 18-May-2022 | Merger/Acquisition | Drug Discovery | ||
| Inzen | 18-May-2022 | Merger/Acquisition | Drug Discovery |
Sonata Therapeutics FAQs
-
When was Sonata Therapeutics founded?
Sonata Therapeutics was founded in 2022.
-
Where is Sonata Therapeutics headquartered?
Sonata Therapeutics is headquartered in Watertown, MA.
-
What is the size of Sonata Therapeutics?
Sonata Therapeutics has 54 total employees.
-
What industry is Sonata Therapeutics in?
Sonata Therapeutics’s primary industry is Drug Discovery.
-
Is Sonata Therapeutics a private or public company?
Sonata Therapeutics is a Private company.
-
What is Sonata Therapeutics’s current revenue?
The current revenue for Sonata Therapeutics is .
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
